Drugs / Biejia-Ruangan compound
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT06923176 | Apr 2025 → Apr 2031 expected | hepatocellular carcinoma | Zhiyun Yang | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07481032 | Apr 2026 → Apr 2028 expected | chronic hepatitis B virus infection, cirrhosis of liver, hepatocellular carcinoma | Nanfang Hospital, Southern Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Biejia-Ruangan compound | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06923176 ↗ |